Date: 09-Oct-2019

GSK recalls popular heartburn medicine Zantac: U.K. medicines watchdog

GlaxoSmithKline Plc is recalling its heartburn medicine Zantac as a "precautionary measure" due to a probable cancer-causing impurity in the drug, Britain's medicines watchdog said on Tuesday. The move follows the U.S. Food and Drug Administration discovery last week of "unacceptable levels" of a cancer-causing impurity in Zantac and its generic versions known chemically as ranitidine. GSK is recalling all unexpired stock of Zantac from pharmacies due to possible contamination with an impurity N-nitrosodimethylamine (NDMA), the Medicines and Healthcare products Regulatory Agency (MHRA) said. The company was not immediately available for a comment.